| Bioactivity | CaV1.3 antagonist-1 is a potent and highly selective CaV1.3 L-type calcium channel (LTCC) antagonist with an IC50 of 1.7 μM. CaV1.3 antagonist-1 inhibits CaV1.3 LTCC >600-fold more potently than CaV1.2 LTCC. CaV1.3 antagonist-1, a cyclopentyl derivative, has the potential for Parkinson's disease research[1]. |
| Invitro | CaV1.3 antagonist-1 (Compound 8; 5 μM) exhibits 31.2% and 4.4% inhibition for CaV1.3 and CaV1.2 channel current in HEK293 cells, respectively. This correlates with the results of the FLIPR assay[1]. |
| Name | CaV1.3 antagonist-1 |
| CAS | 1391385-57-1 |
| Formula | C17H19ClN2O3 |
| Molar Mass | 334.80 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Soosung Kang, et al. CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Nat Commun. 2012;3:1146. |
CaV1.3 antagonist-1
CAS: 1391385-57-1 F: C17H19ClN2O3 W: 334.80
CaV1.3 antagonist-1 is a potent and highly selective CaV1.3 L-type calcium channel (LTCC) antagonist with an IC50 of 1.7
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.